key: cord-0265859-25pf09ab
authors: Chen, Elaine C.; Gilchuk, Pavlo; Zost, Seth J.; Ilinykh, Philipp A.; Binshtein, Elad; Huang, Kai; Myers, Luke; Bonissone, Stefano; Day, Samuel; Kona, Chandrahaas R.; Trivette, Andrew; Reidy, Joseph X.; Sutton, Rachel E.; Gainza, Christopher; Monroig, Summer; Davidson, Edgar; Saphire, Erica Ollmann; Doranz, Benjamin J.; Castellana, Natalie; Bukreyev, Alexander; Carnahan, Robert H.; Crowe, James E.
title: Systematic analysis of human antibody response to ebolavirus glycoprotein reveals high prevalence of neutralizing public clonotypes
date: 2022-01-13
journal: bioRxiv
DOI: 10.1101/2022.01.12.476089
sha: 61853a1bb8a045adf6ac03fc8674b2685d380435
doc_id: 265859
cord_uid: 25pf09ab

Understanding the human antibody response to emerging viral pathogens is key to epidemic preparedness. As the size of the B cell response to a pathogenic virus protective antigen is undefined, we performed deep paired heavy and light chain sequencing in EBOV-GP specific memory B cells, allowing analysis of the ebolavirus-specific antibody repertoire both genetically and functionally. This approach facilitated investigation of the molecular and genetic basis for evolution of cross-reactive antibodies by elucidating germline-encoded properties of antibodies to EBOV and identification of the overlap between antibodies in the memory B-cell and serum repertoire. We identified 73 public clonotypes to EBOV, 20% of which encoded antibodies with neutralization activity and capacity to protect in vivo. This comprehensive analysis of the public and private antibody repertoire provides insight into the molecular basis of the humoral immune response to EBOV-GP, which informs vaccine design of new vaccines and improved therapeutics.

. From this class-switched B cell population, we identified EBOV 165 GP-reactive cells using biotinylated EBOV GP and fluorescently labeled streptavidin ( Figure  166 1B). From 7 x 10 7 total CD19+ B cells, we sorted ∼100,000 GP-reactive class switched B-cells; 167 roughly 3% of the class-switched B cell population bound EBOV GP ( Figure 1C) . These GP-168 reactive cells then were single-cell sequenced using a single-cell encapsulation automated system 169 (Chromium Controller; 10X Genomics). A total of 15,191 paired antibody heavy and light chain 170 variable region sequences were obtained from the single-cell sequencing experiment. As a 171 control experiment in parallel, a PBMC sample from a healthy adult with no history of exposure 172 to EBOV also was subjected to the same workflow. For the control subject, IgM -IgD -CD19 + B-173 cells were sorted and subjected to single-cell sequencing to obtain 10,960 total paired heavy and 174 light chain sequences for this non-specified-antigen-specific B cell set ( Figure 1C) . 175 176 Genetic characteristics of the memory B cell repertoire to EBOV GP 177 Immunoglobulin features such as inferred variable gene use and percent identity to inferred 178 germline genes were identified using the PyIR informatics pipeline based on IgBLAST (Soto et 179 al., 2020; Ye et al., 2013) . To examine the different variable genes used in antibodies specific to 180 the EBOV GP that were captured from our GP-reactive B cell sorting experiment, the frequency 181 of each IGHV or IGKV/IGLV gene used was measured and normalized to a percent using the 182 total number of sequences acquired as 100%. The same analysis also was performed on the 183 10,960 total paired sequences for B cells obtained by from the control subject ( Figure 1C) . 184 IGHV1-69 was the most frequently used heavy chain variable gene (9.2%), followed by IGHV1-185 02 (6.3%) and IGHV4-34 (7.5%) ( Figure 1E) . For light chains, IGKV1-39 was the most 186 frequently used light chain variable gene (12.2%). Gene use for the non-specified-antigen-187 specific antibodies from the control subject are plotted for comparison. The median amino acid 188 lengths of CDRH3 or CDRL3 for the EBOV GP-specific repertoire was 17 or 9, respectively. In 189 comparison, the median amino acid lengths of CDRH3 or CDRL3 for the non-specified-antigen-190 specific repertoire were 15 or 9, respectively. For the EBOV GP-specific repertoire, the average 191 identity to germline was 94.2% for the heavy chain and 96.1% for the light chain, with the 192 median number of mutations being 16 or 10 amino acids respectively. As a comparison, in the 193 non-specified-antigen-specific repertoire, the average identity to germline was 95.6% or 97.2% 194 on the heavy or light chain, with the median number of mutations being 12 or 7 amino acids, 195 respectively. These findings indicate that the EBOV GP-specific repertoire is slightly more 196 mutated than the non-specified-antigen repertoire, with slightly longer CDR3s in heavy and light 197 chains, although it is also possible that it is due to differences between individuals. 198 199

To identify clonal families to which each sequence belongs, sequences were clustered by binning 201 the clones based on the inferred immunoglobulin heavy variable (IGHV) gene, immunoglobulin 202 heavy joining (IGHJ) gene, and the amino acid length of the CDRH3. Then, sequences were 203 clustered according to 80% nucleotide sequence identity in the DNA sequence encoding the 204 CDRH3. Next, sequences were binned further based on the inferred immunoglobulin light 205 variable gene (IGLV or IGKV) and immunoglobulin light joining (IGLJ and IGKJ) genes and 206 80% nucleotide sequence identity in the DNA sequence encoding the CDRL3. From the 15,191 207 total paired sequences derived from our EBOV GP-specific sort, 10,087 clonal families were 208 identified. Of these, 6,923 were singlets (meaning there were no other sequences that clustered 209 with that single sequence). Additionally, 2,382 were doublets, meaning two sequences clustered 210 together, but did not cluster with any other sequence. We defined clusters as clonally expanded 211 families if they included five or more sequences and found 224 such clonal families. To compare 212 the distribution of EBOV GP-reactive clonal families to those of the control subject, we applied 213 the same clustering scheme to the non-antigen-specific sequence set. From the 10,960 sequences 214 in that individual, 10,527 clonal families were identified. From that set, 10,172 were singlets and 215 305 were doublets. Only 21 clonally expanded clonal families were observed in the control 216 subject ( Figure 2B) . 217 218 We next estimated the size and diversity of the EBOV GP-reactive memory B cell repertoire in 219 the convalescent donor using rarefaction analysis (Saary et al., 2017) . In this work, we used the 220 clonal families determined through the clustering scheme described above as taxonomic units or 221 species. We first plotted species richness that is present in the defined sample set; species 222 richness measures the number of species, or in our case clonal families. The species richness 223 curve continually increased but never plateaued, meaning that as our sequencing depth increased, 224 we continued to discover new clonal families. This finding suggested that even at this substantial 225 depth of sequencing, we did not identify all EBOV GP-specific clonal families present in this 226 donor. The same approach was used for the sequences from the control subject, for whom the 227 species richness curve exhibited a steeper slope than the EBOV GP-specific curve. This 228 comparison indicates the EBOV GP-specific sequence set is less diverse than the non-GP-229 specific sequence set that was captured in our experiments ( Figure 1D) . 230 231 Next, we calculated the Chao diversity index (Chao1) (Hsieh et al., 2016) , which estimates the 232 number of species there is likely to be in the sample set. The Chao diversity index for the EBOV 233 GP-reactive antibody sequences at a sample depth of 90% of the repertoire was 20,329. This 234 value suggests that there are an estimated 20,329 clonal families present in the EBOV GP-235 specific antibody repertoire within this donor, of which we identified 10,087 (~50% of the total). 236

The estimated total of the non-antigen-specific antibody sequence set at a sample depth of 90% 237 is 177,374, from which we have identified 10,527 clonal families. However, the number for the 238 non-GP-specific repertoire is not a confident estimate as this value grows at every new sample 239 depth, and it is likely that the number of clonotypes in a non-GP-specific repertoire is much 240 higher than estimated here. In contrast, the estimated number of clonal families stayed consistent 241 with increasing depth for the EBOV GP-reactive antibody sequence set estimate, giving 242 confidence in the estimated number of total species. This outcome can be visualized in Figure  243 1D, as the EBOV GP-specific repertoire unique species plot exhibits plateauing at a much lower 244 sample depth. With more than a ten-fold difference in estimated diversity, this finding indicates 245 that the EBOV GP-reactive antibody repertoire is much less diverse and has fewer clonal 246 families compared to a GP-antigen-specific repertoire. Therefore, through modeling, we 247 We recently described a proteo-genomic analysis for identifying EBOV-specific 300 immunoglobulin proteins in convalescent human plasma from the same donor we used in this 301 study (Gilchuk et al., 2021) . EBOV GP-specific polyclonal antibodies from the donor plasma 302 were purified and subjected to high-resolution liquid chromatography coupled to tandem mass-303 spectrometry, yielding sequences of antibody proteins present in plasma. Immunoglobulins in the 304 plasma repertoire were identified as present in the memory B cell repertoire if there was over 305 50% coverage in the CDR3 region and a general peptide coverage over 100% of the CDR3, as 306 previously described (Gilchuk et al., 2021) . A subset of 1,512 EBOV GP-specific memory B cell 307 antibody variable gene sequences was used for the original study. Here, since we had obtained a 308 much (10-fold) larger memory B cell repertoire from heavy and light chain paired sequences 309 from this individual, we reinvestigated the portion of antibodies that is shared between the 310 plasma immunoglobulin protein and memory B cell receptor repertoires. Therefore, it is likely that many of the polyclonal antibodies found in the plasma come from non-322 clonally-expanded memory B cell families. When identifying the V H gene usages of these serum 323 identified antibodies, the highest used genes were IGHV1-2 and IGHV3-11 at 10%. Following, 324 IGHV4-34, IGHV3-21, IGHV1-69, and IGHV4-59 at 8%, 8% 7%, and 6% of the total serum 325 antibodies identified respectively. Additionally, despite the large amount of gene sequences used 326 here as a reference set for the proteomics studies, there appears to be a relatively small Although we obtained unprecedented depth for paired heavy and light chain variable gene 333 sequencing from single antigen-specific B cells from this donor, the depth of sequencing that can 334 be acquired by bulk heavy or light chain antibody variable gene sequencing (without pairing) is 335 still far superior. Therefore, to investigate the evolution of cross-reactive antibodies, we clustered 336 sequences obtained from single cell paired sequencing with those obtained from bulk sequencing 337 from the same leukapheresis sample PBMCs from this donor and constructed phylogenetic trees 338 detailing the evolution of these cross-reactive antibodies versus that of monospecific antibodies. 339 340 Several clonally-expanded neutralizing antibodies with varying reactivities to the different GP 341 and predicted epitopes were selected for further investigation of their evolution. To increase the 342 amount of sequencing to use for phylogenetic analysis, heavy and light chain bulk sequencing 343 was performed on PBMCs originating from this donor without antigen-specific sorting. The 344 heavy chains from all clonal families previously identified in the single-cell sequencing were 345 then clustered with those in the heavy chain bulk sequencing, and the light chains were clustered 346 similarly. Sequences were clustered based on the same V and J gene usage as well as 80% 347 identity of the CDR3 nucleotide sequences. Using the clustered sequences for each clonal family, 348 maximum likelihood trees were constructed for both heavy and light chains, and the unmutated 349 common ancestor (UCA) was inferred for each clonal family. 350

To determine whether the antiviral function of each clonal family was due to germline-encoded 352 reactivity or due to somatic mutations that accumulated during antibody evolution, we 353 investigated the binding and neutralization profile for each inferred UCA (Table S1) UCA also maintained its cross-reactive neutralizing activity for both EBOV and BDBV, even 377 though its neutralization potency for BDBV is relatively low at 50 µg/mL ( Figure 3D) . 378 Therefore, it is likely that these antibodies started off with neutralizing properties mostly for 379 EBOV with weak inhibition of BDBV but evolved to gain potency for the two strains ( Figure  380 3G). EBOV-591-UCA also retained its ability to neutralize all three strains, however, its potency 381 to SUDV dropped substantially. EBOV-591 also is encoded by IGHV1-2 but uses a different 382 light chain gene, IGKV4-1 ( Figure 3D, H) . vaccination. These sequences then were clustered to identify public clonotypes. Sequences were 398 first binned by their V and J gene use and CDR3 length. Next, sequences were clustered by 60% 399 on the CDR3 nucleotide sequence and binned by the light chain V and J gene. Clusters with 400 sequences from two or more of the 12 individuals then were identified as public clonotypes. A 401 total of 73 public clonotypes were identified. One public clonotype was shared among 6 donors. 402

Another was shared among four donors. Five public clonotypes were shared between three 403 donors, and the remaining were all shared between two donors ( Figure 4A ). All 294 members of 404 the 73 public clonotypes were synthesized and expressed as recombinant IgGs as previously 405 described (Gilchuk et al., 2020a) and tested by ELISA for binding to EBOV, BDBV, SUDV, 406 MARV GP, or EBOV sGP. Next, they were tested for binding to cleaved EBOV GP (GP cl ) or 407 intact EBOV GP (GP ecto ), and for neutralization of VSV-EBOV. As most members of each 408 public clonotype were expected to share similar functional profiles due to genetic similarity, the 409 predicted functional profile was determined by identifying the dominant functional phenotype in 410 each public clonotype (Figure 4C, S5) . results. The remaining three antibodies did not bind to GP in ELISA and therefore, we used 456 negative stain electron microscopy (EM) to identify the antigenic site recognized by these 457 neutralizing antibodies. 458

Fab-EBOV GP complexes were imaged with a representative mAb from each public clonotype 460 group (Figure 6B, S4) . Although EBOV-598 (Group 3.04), EBOV-786 (Group 2.28), and 461 EBOV-854 (Group 2.33) and other members of their respective public clonotype groups did not 462 exhibit binding to GP in ELISA they did show binding to GP cl in a cell-surface display assay and 463 had neutralization properties (Figure 4C , 5A, S5); these mAbs complexed with EBOV GP for 464 EM studies, and 3D reconstructions were made. These low-resolution reconstructions show that 465 all three of these mAbs as well as EBOV-817, which competed for binding with the reference 466 antibody EBOV-515, bind the base region of GP. Although EBOV-852 was visualized on the 467 grid, and we were able to obtain 2D images of it in complex with GP, we were unable to obtain a 468 REST. In BDBV, TAFV, and MARV, this residue is substituted to an alanine. Therefore, this 494 finding likely explains the cross-reactive neutralization of EBOV and SUDV but not BDBV by 495 EBOV-598, which was unexpected as EBOV and BDBV GP are generally more similar in 496 sequence identity than EBOV and SUDV GP. A single critical residue was identified for EBOV-497 786, EBOV-709, and EBOV-823 ( Figure 6C) . The one critical residue indicated for EBOV-786 498 was S46. This residue is conserved between EBOV and BDBV but not SUDV GP (in which the 499 serine changes to a threonine). However, this residue is also conserved in TAFV. Lastly, the 500 critical residue identified for EBOV-709 and EBOV-823 is W275. This residue is conserved 501 across EBOV, BDBV, SUDV, TAFV, and REST, and sits in the glycan cap, also mirroring the 502 results of the competition-binding ELISA data as these antibodies compete with mAb 13C6 503 ( Figure 5A ) and the results of the negative stain EM studies ( Figure 6B) . Therefore, it is likely 504 that these findings explain the capacity of EBOV-709 and EBOV-852 to neutralize EBOV and 505 BDBV but not SUDV. 506 507 Surveying the level of publicness in identified public clonotypes 508

There are many methods for identifying public clonotypes, using multiple identity thresholds or 509 junction matching techniques. Our approach used a paired heavy and light chain gene sequence 510 set and we characterized the functional phenotypes of all public clonotype antibodies identified, 511 allowing us to use a sequence identity threshold on the lower end of common practice. Using the 512 same clustering scheme of binning on the heavy chain V and J gene as well as CDR3 length, we 513 next clustered the public clonotypes identified at 70% and 80% similarity on the CDR3 514 nucleotide sequence and binned them at the back end by matching on the light chain V and J 515 gene. Next, we identified the antibodies that fell out of each public clonotype cluster at each 516 threshold of 60%, 70%, and 80% and investigated if antibodies that fell out at each threshold 517 shared similar functional phenotypes that would differentiate them from the main group (Table  518 S2). We did not detect a difference in the functional binning of antibodies when clustering at 519 differing identity thresholds. Figure S2) . Together, we are confident that our approach of using a 534 threshold of 60% on the CDRH3 sequence in conjunction with binning on the CDRH3 length 535 and both heavy and light chain V and J genes is successful in identifying public clonotypes when 536 using paired sequence sets. 537 538

To investigate if the neutralizing activity of these public clonotypes was due to germline-540 encoded reactivity or the result of somatic mutations, we investigated the equivalent germline-541 encoded antibodies for each public clonotype. We aligned each heavy and light chain variable 542 region sequences to its respective germline gene sequence and reverted residue that differed from 543 the germline gene to the inferred germline residue. Each germline-revertant (GR) antibody then 544 was tested to see if the GR version of the antibody shared similar properties to its mutated 545 counterparts ( Table S1) . All GR antibodies were tested for binding to EBOV, BDBV, or SUDV 546 GP. Additionally, they were tested for neutralization of VSV-EBOV, -BDBV, or -SUDV. 547

Although most GR antibodies did not retain binding to either GP or neutralize either virus, three 548 GR antibodies retained functional activity compared to their mutated counterparts ( Figure 5A) . 549 EBOV-852-GR, encoded by IGHV1-2/IGLV2-8 retained ability to bind and neutralize EBOV 550 and BDBV. EBOV-709-GR, encoded by IGHV1-69/IGLV1-44 retained ability to bind and 551 neutralize EBOV but only partially to BDBV (Figure 5C ). EBOV-857, encoded by IGHV3-552 13/IGKV3-20 retained its ability to bind and neutralize EBOV (Figure 5A) . These findings 553 indicate that germline genes in these public clonotypes encode antibodies with critical residues 554 that not only mediate binding but also neutralization. 555

We then tested these public clonotypes and their level of protection in vivo in mice against 558 EBOV (Mayinga strain). Antibodies were delivered at 5 mg/kg 1 day after inoculation with 559 EBOV. Scores on protection from death, weight loss, and disease were measured for 28 days. point tested, about 9 months after infection. It should be noted that each of those >20,000 581 clonotypes contains many somatic variants (for instance, the largest clonal family we recovered 582 had 21 sequences within its single lineage in this study). Thus, the size and complexity of the 583 response to a single viral protein is enormous. 584 585 A strength of the antibody discovery approach used here was that we not only obtained variable 586 gene sequences, but also those sequences were authentically paired heavy and light chain 587 sequences from single cells. This approach allowed us to express representative naturally 588 occurring mAbs of each of the clonotypes of interest so that we could validate their specificity 589 and define their cross-reactivity and neutralizing potency. Here, we observed that 45% of the 590 clonally expanded antibody repertoire neutralized EBOV. About two-thirds of the neutralizing 591 clones targeted the glycan cap region of the GP. This finding shows that, even though many have 592 provided an opportunity to mine for public clonotypes specific to EBOV GP but also posed 647 technical challenges for data analysis. We sought to identify public clonotypes using both heavy 648 and light chain sequences, a workflow that is only achievable with paired sequences from single 649 B cells. Identity thresholds used to identify public clonotypes in variable gene sequence sets vary 650 greatly in the field. We chose an identity threshold for identification of public clonotypes on the 651 lower end of common conventions, but our confidence in these assignments was supported by 652 both heavy and light chain gene segment assignments and with functional testing of recombinant 653 antibodies encoded by these sequences. As we tested all 294 members of the public clonotypes 654 functionally, we were in a unique position to investigate different clustering thresholds for 655 identifying public clonotypes and tested how those thresholds affected the grouping of antibodies 656 with functional phenotypes. As clustering at higher thresholds did not necessarily bin antibodies 657 into tidier functional phenotype bins, we conclude that when mining for public clonotypes within 658 an antigen-specific sequence set using paired sequencing from single cells, a threshold of 60% 659 identity in the CDRH3 is sufficient. 660 661 It is highly desirable to identity germline-encoded pan-ebolavirus cross-reactive antibodies to 662 support rational vaccine design and testing efforts. Here we identified two V H genes that often 663 encode cross-reactive antibodies at the germline level: IGHV1-69 and IGHV1-02. For IGHV1-69 , 664 a structural explanation is now possible. IGHV1-69/IGHJ6-encoded antibodies have been 665 described to target the mucin-like domain (MLD) cradle, exploiting hydrophobic residues 666 encoded by the germline of these gene segments bind and destabilizes the GP quaternary 667 structure and therefore blocking cleavage required for receptor binding (Murin et al., 2021) . 668

Within the antibodies described, potency was acquired through somatic hypermutation. 669

However, antibodies in this class had cross-reactive neutralizing proprieties regardless since they 670 target the conserved MLD anchor and cradle. The molecular and structural determinants of the 671 cross-reactive activities associated with IGHV1-02-encoded antibodies have yet to be described. 672

Here, the data reveal that the cross-reactive neutralizing properties of antibodies encoded by 673 IGHV1-02 are germline-encoded. IGHV1-02 also has been shown to encode broadly neutralizing 674 antibodies for HIV, due to hydrophobic residues in the CDR2 similar to those encoded by the 675 CDR2 of some alleles of the germline gene IGHV1-69. As all the IGHV1-02-encoded antibodies 676 discovered here competed for binding with the glycan cap mAb 13C6, we predict that IGHV1-02 677 encodes for cross-reactive neutralizing antibodies targeting the glycan cap or MLD region of the 678 GP using a similar mechanism to that of IGHV1-69-encoded antibodies. Previous data had shown that in plasma, there is preferential recognition of the cleaved EBOV 703 GP. However, in our study, it is interesting that when narrowing the antibody characteristics of 704 plasma antibodies identified from clonally expanded families, these antibodies preferentially 705 recognized the intact GP. Therefore, it seems likely that the bulk of plasma antibodies could 706 derive from specificities less common in circulating memory B cells (noted as singlets in our 707 single cell RNAseq repertoire) where a lot of the reactivity for cleaved GP would reside. A 708 technical limitation of plasma proteomic antibody studies is that likely only highly represented 709 antibodies are detected, and therefore this dataset is likely lacking antibodies present at low 710 levels in the plasma. were labeled with recombinant EBOV GP protein that was produced in Drosophila S2 cells as 975 described above and purified by flow cytometric cell sorting using an SH800 cell sorter (Sony) 976 as described previously (Gilchuk et al., 2020b) . Approximately 100,000 cells were FACS-sorted 977 in bulk for downstream paired antibody heavy and light chain variable gene sequence analysis. The DNAs in the final resulting libraries from both library preparation approaches were 1023 quantified using the Qubit 3.0 fluorometer (Thermo Fisher Scientific) prior to size determination 1024 using a Bioanalyzer 2100 (Agilent). Libraries were re-quantified using the KAPA qPCR kit 1025 (KAPA Biosystems) before sequencing on an MiSeq instrument (Illumina) using two separate 2 1026

x 300 bp flow cells (Illumina). 1027

Chain specificity and orientation of the primer Oligo name DNA sequence, 5′ to 3′ Length (base pair)

In-house Heavy reverse  IgExp_Hconst  GGAGACGGTGACCAGGGT  18  Heavy forward  IgExp_H1  CARRTNCAGCTGGTRCAGTC  20  IgExp_H2  CAGRTCACCTTGARGGAGTC  20  IgExp_H3  SARGTGCAGCTGGTGGAGTC  20  IgExp_H4  CAGSTGCAGCTRSAGGAGTC  20  IgExp_H5  GARGTGCAGCTGGTGCAGTC  20  IgExp_H6  CAGGTACAGCTGCAGCAGTC  20  IgExp_H7  CAGGTGCAGCTGGTGCAGTC  20  Kappa reverse  IgExp_Kconst  AGATGGTGCGGCCGCAGT  18  Kappa forward  IgExp_K1  GMCATCCRGWTGACCCAG  18  IgExp_K2  GAKRTTGTGATGACYCAG  18  IgExp_K3  GAAATWGTRWTGACRCAG  18  IgExp_K4  GACATCGTGATGACCCAG  18  IgExp_K5  GAAACGACACTCACGCAG  18  IgExp_K6  GAWRTTGTGMTGACWCAG  18  Lambda forward  IgExp_Lconst  TGGAGCGGCCTTAGGCTG  18  IgExp_L1  CAGTCTGTSBTGACKCAG  18  IgExp_L2  CARTCTGCCCTGACTCAG  18  IgExp_L3  TCCTMTGDGCYRAYWCAG  18  IgExp_L4  CWGCYTGTGCTGACTCAA  18  IgExp_L5  CAGSCTGTGCTGACTCAG  18  IgExp_L6  AATTTTATGCTGACTCAG  18  IgExp_L7  CAGRCTGTGGTGACTCAG  18  IgExp_L8  CAGWCTGTGGTGACCCAG  18  IgExp_L9  CAGCCTGTGCTGACTCAG  18  IgExp_L10  CAGGCAGGGCTGACTCAG  18  IgExp_L11  CGGCCCGTGCTGACTCAG 

100%, while coverage over the entire variable region sequence was above 90%

The descriptive statistics mean ± SEM or mean ± SD 1212 were determined for continuous variables as noted. Curves for antibody binding and 1213 neutralization were fitted after log transformation of antibody concentrations using non-linear 1214 regression analysis. Technical and biological replicates are

RESOURCE AVAILABILITY

Lead Contact: Further information and requests for resources and reagents should be 1218 directed to and will be fulfilled by the lead contact

Additional data are available in the main text or the 1221 supplementary materials. Requests for reagents may be directed to and be fulfilled by the Lead 1222

Materials reported in this study will 1223 be made available but may require execution of a Materials Transfer Agreement

Code availability: The computational pipeline for the clustering analysis as well as the 1225 scripts to analyze gene usages is available on GitHub

Broadly neutralizing antibodies with few somatic 1231 mutations and hepatitis C virus clearance

Serum proteomics expands on high-affinity antibodies in immunized rabbits than deep 1235 B-cell repertoire sequencing alone

A two-antibody pan-ebolavirus cocktail 1239 confers broad therapeutic protection in ferrets and nonhuman primates

Isolation of potent neutralizing antibodies from a 1244 survivor of the 2014 Ebola virus outbreak

A mouse model for 1247 evaluation of prophylaxis and therapy of Ebola hemorrhagic fever

Commonality despite exceptional 1250 diversity in the baseline human antibody repertoire

Vaccine generation of protective Ebola antibodies and 1254 identification of conserved B-cell signatures

Convergent antibody responses to the 1258 SARS-CoV-2 spike protein in convalescent and vaccinated individuals

Cleavage efficient 2A peptides for high level monoclonal antibody expression in CHO 1262 cells

Structural basis for a convergent immune response against Ebola virus

Protective monotherapy against lethal Ebola 1270 virus infection by a potently neutralizing antibody

Longitudinal analysis of the human B 1274 cell response to Ebola virus infection

Improvements to B cell clonality 1277 analysis using PCR amplification of immunoglobulin light chain genes

Genetic and structural basis for SARS-CoV-2 variant 1281 neutralization by a two-antibody cocktail

Polyclonal and convergent 1285 antibody response to Ebola virus vaccine rVSV-ZEBOV

Properties of replication-competent vesicular 1291 stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses

Integrated pipeline for the accelerated discovery 1296 of antiviral antibody therapeutics

Proteo-genomic analysis identifies two major 1300 sites of vulnerability on Ebolavirus glycoprotein for neutralizing antibodies in convalescent 1301 human plasma

Multifunctional pan-Ebolavirus antibody 1305 recognizes a site of broad vulnerability on the Ebolavirus glycoprotein

Analysis of a therapeutic antibody cocktail 1310 reveals determinants for cooperative and broad Ebolavirus neutralization

iNEXT: an R package for rarefaction and 1314 extrapolation of species diversity (Hill numbers)

Ebolavirus chimerization for the development of a mouse model for 1318 screening of Bundibugyo-specific antibodies

Chimeric filoviruses for identification and characterization of monoclonal antibodies

Vaccine-induced antibodies that 1326 neutralize group 1 and group 2 Influenza A viruses

Monoclonal antibody therapy for Ebola virus disease

Automated electron microscope tomography using robust prediction 1332 of specimen movements

Large-scale network analysis reveals 1335 the sequence space architecture of antibody repertoires

Vaccination with 1339 prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and 1340 antigenically diverse antibody responses

Convergence of a common solution for broad 1344 ebolavirus neutralization by glycan cap-directed human antibodies

Negative staining and image classification -1347 powerful tools in modern electron microscopy

Rapid 1351 development of broadly influenza neutralizing antibodies through redundant mutations

Development of clinical-stage human 1356 monoclonal antibodies that treat advanced Ebola virus disease in nonhuman primates

UCSF Chimera--a visualization system for exploratory research and 1361 analysis

cryoSPARC: algorithms 1364 for rapid unsupervised cryo-EM structure determination

Reverse 1367 vaccinology 2.0: Human immunology instructs vaccine antigen design

Therapeutic monoclonal antibodies for Ebola virus 1371 infection derived from vaccinated humans

CTFFIND4: Fast and accurate defocus estimation from 1374 electron micrographs

RTK: efficient rarefaction analysis 1377 of large datasets

Prolonged evolution of the 1381 human B cell response to SARS-CoV-2 infection

A vaccine-induced public antibody protects against 1385 SARS-CoV-2 and emerging variants

Multi-Donor longitudinal antibody 1389 repertoire sequencing reveals the existence of public antibody clonotypes in HIV-1 infection

Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen

High frequency of shared clonotypes in 1398 human B cell receptor repertoires

PyIR: a scalable wrapper for processing billions of 1402 immunoglobulin and T cell receptor sequences using IgBLAST

Neutralizing and protective human 1406 monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein

Sequence signatures of two public 1412 antibody clonotypes that bind SARS-CoV-2 receptor binding domain

Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early 1416 pathogenesis events and high-throughput antiviral drug screening

Design and standardization 1420 of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene 1421 recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action 1422 BMH4-CT98-3936

Antibodies from a human survivor 1426 define sites of vulnerability for broad protection against Ebolaviruses

Early human B cell response to ebola 1430 virus in four U.S. survivors of infection

IgBLAST: an immunoglobulin variable 1433 domain sequence analysis tool

Structural basis of a shared antibody response to SARS-CoV-2

Structural repertoire of HIV-1-neutralizing 1441 antibodies targeting the CD4 supersite in 14 donors

Canonical features of human antibodies recognizing 1445 the influenza hemagglutinin trimer interface

Rapid isolation and profiling of a diverse panel of 1449 human monoclonal antibodies targeting the SARS-CoV-2 spike protein

sequences used for the one-step RT-PCR approach are listed below. The thermal cycling 1001 parameters for both sets of reactions were as follows: 50°C for 30 min; 94°C for 2 min; 24 cycles 1002 of 94°C for 15 s, 58°C for 30 s, and 68°C for 1 min; 68°C for 10 min. PCR products were 1003 purified using a 2% gel cassette on a PippinHT system (Safe Science) targeting 200-500 bp 1004 amplicons (Sage Science). Illumina indexing and adapter ligation was performed using the 1005 NEBNext® Ultra DNA Library Prep kit (NEB) . 1006

In the second library preparation approach, 4 µL total RNA was shipped to and processed by 1008AbHelix, LLC (www.abhelix.com, South Plainfield, NJ, USA). Briefly, RNA samples were 1009 reverse-transcribed using oligo d(T) 18 and SuperScript IV Reverse Transcriptase (Thermo 1010 Fisher Scientific) followed by Ampure XP bead purification (Beckman Coulter). The purified 1011 RT products were divided evenly for the first round of PCR amplification specific to human IgG, 1012IgK, IgL, IgM, or IgA. The 5′ multiplex PCR primers are designed within the leader sequences 1013 of each productive V-gene and the 3′ primers within the constant regions but in close 1014 approximation to the J-C junctions. The resulting first-round PCR products were purified with 1015 magnetic beads and subjected to the second round of PCR amplification to add Illumina index 1016 and adapter sequences. The resulting PCR products were purified with Ampure XP ( Together with sequences derived from this paper, public clonotypes were determined by genetic 1040 similarities of antibody sequences using the following clustering scheme. They were first binned 1041 by V H and J H gene and CDRH3 amino acid length. Sequences within each bin then were 1042 clustered according to 60% sequence similarity on their CDRH3 nucleotide sequence. Lastly, 1043 sequences were binned if they used the same light chain V and J gene. Clusters of sequences 1044 meeting the described criteria and contained sequences originating from two or more individuals 1045 were deemed public clonotypes. 1046 1047 Bulk sequence clustering. Sequences within a same paired sequence cluster was taken. These 1048 sequences were then used to search for sequences within the bulk sequence dataset. Sequences 1049 sharing the same V and J gene as well as 80% similarity on the CDR3 sequence were then 1050 clustered together. SerialEM (Mastronarde, 2005) . All images were taken at 50,000× magnification with a pixel 1194 size of 2.18 Å per pixel in low-dose mode at a defocus of 1.5 to 1.8 µm. The total dose for the 1195 micrographs was around 30 e−/per Å 2 . Image processing was performed using the cryoSPARC 1196 software package (Punjani et al., 2017) . Images were imported, CTF-estimated with 1197 CTFFIND4 (Rohou and Grigorieff, 2015) and particles were picked automatically with template 1198 picker (a part of cryoSPARC). The particles were extracted with a box size of 160 pixels and 1199 binned to 80 pixels (pixel size of 4.36 Å/pix). Multiple 2D class averages were performed, and 1200 good classes were selected for ab-initio 3D map reconstruction. At the final step, the data sets 1201 were refined. Maps were imaged using Chimera software (Pettersen et al., 2004) . 1202 1203 Proteogenomic analysis. The immunoproteogenomic platform Alicanto (Bonissone, 2021) was 1204 used for identifying antibody sequences and visualizing proteomics results, similar to a previous 1205 study (Gilchuk et al., 2021) . Briefly, the variable region sequences of antigen-sorted and 1206 sequenced B cells were analyzed and annotated by Alicanto. The tandem mass spectra were 1207 searched against this custom antibody database. Antibody clones were determined as present if 1208